-
THE BLUES CLOUD THE VIEW: PROXY DEPRESSION IS ASSOCIATED WITH LOWER DYADIC AGREEMENT ON EQ-5D-5L
Feb 25, 2026, 14:40 PM -
TRANSLATING REGIONAL SYNERGIES INTO CLINICAL OUTCOMES: STRUCTURAL ANALYSIS OF THE MEDICON VALLEY CLUSTER AND HOW IT BECAME A GLOBAL HEALTH INNOVATION HUB
Feb 25, 2026, 14:40 PM -
PATIENT CHARACTERISTICS, TREATMENT PATTERNS, AND DIRECT HEALTHCARE BURDEN OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN DUBAI: A RETROSPECTIVE CLAIMS DATABASE ANALYSIS (2022-2023)
Feb 25, 2026, 14:40 PM -
BUDGET IMPACT ANALYSIS OF ASCIMINIB FOR THIRD-LINE TREATMENT OF CHRONIC MYELOID LEUKEMIA : A FIVE-YEAR PAYER PERSPECTIVE
Feb 25, 2026, 14:40 PM -
BUDGET IMPACT OF CONTINUOUS AMBULATORY ECG MONITORING: A REAL-WORLD DATA MODEL
Feb 25, 2026, 14:40 PM -
HOSPITALS' TRANSITIONS TO INCREASED OUTPATIENT CARE: IS THERE AN IMPACT ON HOSPITAL-WIDE 30-DAY READMISSIONS? AN ANALYSIS OF DATA FROM THE CENTERS FOR MEDICARE AND MEDICAID SERVICES, 2014-2023
Feb 25, 2026, 14:40 PM -
EVIDENCE-BASED PICO MAPPING FOR EU JOINT CLINICAL ASSESSMENT (JCA) USING A REAL-TIME AI-ASSISTEDLIVINGSYSTEMATIC LITERATURE REVIEW (REAL-SLR): AN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) CASE STUDY
Feb 25, 2026, 14:40 PM -
ASSOCIATION BETWEEN GLP-1 RECEPTOR AGONIST INITIATION AND ALCOHOL USE DISORDER AND ALCOHOL-RELATED MEDICAL CONDITIONS IN A U.S. ADMINISTRATIVE CLAIMS DATABASE
Feb 25, 2026, 14:40 PM -
BEYOND THE BLACK BOX: A NICE- AND CDA-ALIGNED TRANSPARENT GENERATIVE AI FRAMEWORK FOR HEOR EVIDENCE SYNTHESIS AND GENERATION
Feb 25, 2026, 14:40 PM -
INVESTIGATING THE COST-EFFECTIVENESS OF COMBINED COGNITIVE TEST, GUT MICROBIOTA SCREENING, AND LECANEMAB TREATMENT FOR EARLY ALZHEIMER'S DISEASE IN CHINA
Feb 25, 2026, 14:40 PM -
STAFFING LEVELS AND PERFORMANCE OF HEALTHCARE IN ROMANIA IN 2023
Feb 25, 2026, 14:40 PM -
HOW PAYERS READ THE TEA LEAVES: ECONOMIC AND FORMULARY SIGNALS FROM IRA AND MFN?
Feb 25, 2026, 14:40 PM -
US ICER ASSESSMENT APPROACHES TO SURVIVAL EXTRAPOLATION: A REVIEW AND CASE STUDY
Feb 25, 2026, 14:40 PM -
INCORPORATION OF PATIENT AND CLINICIAN FEEDBACK INTO DRUG REIMBURSEMENT RECOMMENDATIONS AT CANADA’S DRUG AGENCY
Feb 25, 2026, 14:40 PM -
ECONOMIC VALUE OF RELAPSE RATE REDUCTION WITH OFATUMUMAB VERSUS COMPARATOR DISEASE-MODIFYING THERAPIES IN RELAPSING MULTIPLE SCLEROSIS: A FIVE-YEAR BUDGET IMPACT ANALYSIS WITH CLINICAL OUTCOME OFFSETS
Feb 25, 2026, 14:40 PM -
EFFICACY OF PANITUMUMAB VS. CETUXIMAB PLUS CHEMOTHERAPY IN RECURRENT OR METASTATIC SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK: AN ANCHORED MATCHING-ADJUSTED INDIRECT COMPARISON
Feb 25, 2026, 14:40 PM -
COST-MINIMIZATION ANALYSIS OF OCTOCOG ALFA VERSUS EMICIZUMAB PROPHYLAXIS IN PATIENTS WITH HEMOPHILIA A WITHOUT INHIBITORS IN CENTRAL AMERICA, ECUADOR AND PERÚ
Feb 25, 2026, 14:40 PM -
ECONOMIC BURDEN OF HEMOPHILIA B IN THE EUROPE: A SYSTEMATIC LITERATURE REVIEW
Feb 25, 2026, 14:40 PM -
HEALTHCARE RESOURCE UTILIZATION IN LONG-TERM CARE RESIDENTS WITH AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE TREATED WITH BREXPIPRAZOLE
Feb 25, 2026, 14:40 PM -
DISCHARGE DISPOSITION AND NEED FOR ONGOING CARE FOLLOWING HOSPITALIZATION OF HIGH-RISK PATIENTS WITH HOSPITALACQUIREDPRESSURE INJURIES(HAPIS)
Feb 25, 2026, 14:40 PM
